Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options Document date: 2020_3_23
ID: j0i9ozsz_4
Snippet: Gilead Sciences, Inc. in response to the Ebola outbreak in West Africa from 2014 to 2016. In its active triphosphate nucleoside form, remdesivir binds to ribonucleic acid (RNA)-dependent RNA polymerase and acts as an RNA-chain terminator. It displays potent in vitro activity against SARS-CoV-2 with an EC 50 at 48 hours of 0.77 µM in Vero E6 cells [3] . Similar activity has been demonstrated against other zoonotic coronaviruses with EC 50 values .....
Document: Gilead Sciences, Inc. in response to the Ebola outbreak in West Africa from 2014 to 2016. In its active triphosphate nucleoside form, remdesivir binds to ribonucleic acid (RNA)-dependent RNA polymerase and acts as an RNA-chain terminator. It displays potent in vitro activity against SARS-CoV-2 with an EC 50 at 48 hours of 0.77 µM in Vero E6 cells [3] . Similar activity has been demonstrated against other zoonotic coronaviruses with EC 50 values of 0.07 µM demonstrated for both SARS-CoV-1 and MERS-CoV [3] [4] [5] [6] . Remdesivir is highly selective for viral polymerases and is therefore expected to have a low propensity to cause human toxicity. Accordingly, Sheahan et al [6] demonstrated a wide therapeutic index for remdesivir in a human airway epithelial cell model. The drug also displays a high genetic barrier to resistance in coronaviruses and has a long intracellular half-life that allows for once-daily dosing [7, 8] . The dose under investigation for treatment of COVID-19 is 200 mg intravenously (IV) on day 1 followed by 100 mg IV daily for up to 10 days, infused over 30-60 minutes ( Table 1) .
Search related documents:
Co phrase search for related documents- RNA chain terminator and viral polymerase: 1, 2, 3, 4, 5
- RNA chain terminator and vitro activity: 1
- RNA chain terminator and West Africa Ebola outbreak: 1
- RNA polymerase and similar activity: 1, 2, 3, 4, 5, 6
- RNA polymerase and therapeutic index: 1, 2
- RNA polymerase and treatment investigation: 1
- RNA polymerase and viral polymerase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80
- RNA polymerase and vitro activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
- RNA polymerase and West Africa Ebola outbreak: 1, 2
- similar activity and therapeutic index: 1, 2
- similar activity and treatment investigation: 1, 2
- similar activity and viral polymerase: 1, 2
- similar activity and vitro activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- therapeutic index and viral polymerase: 1
- therapeutic index and vitro activity: 1, 2, 3, 4, 5, 6
- treatment investigation and viral polymerase: 1
- treatment investigation and vitro activity: 1, 2
- viral polymerase and vitro activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- vitro activity and West Africa Ebola outbreak: 1, 2
Co phrase search for related documents, hyperlinks ordered by date